BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 6, 2018
View Archived Issues
Lack of LAC is depression target, biomarker
Read More
High-fat diet leads to hair loss?
Read More
Enzyme discovery may improve drug design
Read More
Medicenna's IL-2 superkine shows promising preclinical activity
Read More
Neurodegenerative differences found between the presubiculum and entorhinal cortex in AD
Read More
JCR Pharmaceuticals presents data for JR-141 in mucopolysaccharidosis type II
Read More
HitGen to identify potential new therapies for tuberculosis and malaria
Read More
Salix enters microbiome collaboration with Cedars-Sinai Medical Center
Read More
Immatics begins phase I study of IMA-202 in solid tumors
Read More
IL-23 underlies the development of castration-resistant prostate cancer
Read More
DrugCendR recruiting participants for phase I study of CEND-1 in metastatic pancreatic cancer
Read More
Potential mechanism of purinergic receptor-mediated remyelination discovered
Read More
Global collaboration to develop first-in-class gene therapy for cystic fibrosis
Read More
U.S. researchers patent Nampt activators
Read More
Rodin Therapeutics presents HDAC1 and HDAC2 inhibitors
Read More
XinXiang Medical University divulges ANO5-targeting siRNAs
Read More
Regeneron, bluebird bio to jointly discover immune cell therapies for cancer
Read More
First patient dosed in extension cohort of amcure's phase I/Ib study of AMC-303
Read More
Phase II study of telacebec in tuberculosis begins
Read More